Department of Health
and Human Services (HHS)
and Human Services (HHS)
July 20, 2020
None
National Heart, Lung, and Blood Institute (NHLBI)
The NHLBI Progenitor Cell Translational Consortium (PCTC) seeks to translate advances in progenitor cell biology towards application to heart, lung, and blood diseases.
The PCTC consists of multiple collaborative Research Hubs, supported by an Administrative Coordinating Center (ACC) to provide logistical support to the PCTC activities. The ACC is responsible for solicitation of applications for cores and oversees the peer review and award of subcontracts under the guidance of the NHLBI.
The PCTC ACC will solicit proposals from providers of technology platforms and scientific research services to perform high quality in-depth cell characterization (IDCC) assays in support of the NIH Regenerative Medicine Innovation Project (RMIP) and to collaborate in the development of approaches for IDCC involving regenerative medicine clinical products.
The PCTC ACC is accepting applications for scientific services to conduct in-depth cell characterization for the NIH RMIP now. Proposals must be submitted by close of business (5:00 p.m., EDT) on Monday, September 14, 2020.
Additional information and application instructions can be found at the NHLBI Progenitor Cell Translational Consortium website, https://translationalcells.org/.
Joel Islam, Ph.D.
National Heart, Lung, and Blood Institute (NHLBI)
Telephone: 301-827-1240
Email: islama2@nih.gov